Haemonetics (NYSE:HAE) Raised to Strong-Buy at Wall Street Zen

Haemonetics (NYSE:HAE) was upgraded by equities researchers at Wall Street Zen from a “buy” rating to a “strong-buy” rating in a report issued on Saturday.

Several other equities analysts also recently weighed in on HAE. Citigroup raised their price objective on Haemonetics from $79.00 to $92.00 and gave the company a “neutral” rating in a research note on Friday. Weiss Ratings upgraded Haemonetics from a “sell (d+)” rating to a “hold (c-)” rating in a research report on Thursday, June 25th. JPMorgan Chase & Co. upped their target price on Haemonetics from $62.00 to $86.00 and gave the company a “neutral” rating in a report on Friday. Mizuho raised their price target on Haemonetics from $85.00 to $90.00 and gave the company an “outperform” rating in a research report on Wednesday, July 15th. Finally, BTIG Research lifted their price target on Haemonetics from $84.00 to $96.00 and gave the stock a “buy” rating in a research note on Thursday. One equities research analyst has rated the stock with a Strong Buy rating, six have given a Buy rating and four have assigned a Hold rating to the company. According to MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $90.89.

Haemonetics Trading Down 0.4%

Shares of HAE opened at $87.50 on Friday. Haemonetics has a twelve month low of $47.31 and a twelve month high of $88.58. The company has a current ratio of 3.08, a quick ratio of 1.91 and a debt-to-equity ratio of 1.40. The firm has a market capitalization of $3.98 billion, a P/E ratio of 42.89, a PEG ratio of 1.77 and a beta of 0.52. The firm’s 50-day moving average is $76.98 and its two-hundred day moving average is $66.48.

Haemonetics (NYSE:HAE) last posted its quarterly earnings results on Thursday, August 6th. The medical instruments supplier reported $1.14 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.08 by $0.06. The company had revenue of $339.38 million during the quarter, compared to the consensus estimate of $327.86 million. Haemonetics had a net margin of 7.12% and a return on equity of 27.55%. The company’s revenue for the quarter was up 5.5% on a year-over-year basis. During the same period last year, the firm earned $1.10 EPS. On average, research analysts predict that Haemonetics will post 5.21 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Haemonetics

Institutional investors and hedge funds have recently bought and sold shares of the stock. Kemnay Advisory Services Inc. acquired a new stake in Haemonetics during the 4th quarter valued at $26,000. Leonteq Securities AG acquired a new position in shares of Haemonetics in the fourth quarter worth $30,000. EverSource Wealth Advisors LLC raised its holdings in shares of Haemonetics by 2,640.0% in the second quarter. EverSource Wealth Advisors LLC now owns 411 shares of the medical instruments supplier’s stock worth $31,000 after acquiring an additional 396 shares during the last quarter. Kestra Advisory Services LLC purchased a new stake in shares of Haemonetics in the fourth quarter valued at $34,000. Finally, Bayforest Capital Ltd purchased a new stake in shares of Haemonetics in the fourth quarter valued at $40,000. Hedge funds and other institutional investors own 99.67% of the company’s stock.

Haemonetics News Summary

Here are the key news stories impacting Haemonetics this week:

• Positive Sentiment: Haemonetics reported fiscal Q1 2027 earnings of $1.14 per share, exceeding the $1.07–$1.08 consensus range. Revenue rose 5.5% year over year to $339.4 million, also comfortably ahead of expectations near $327.9 million. The earnings and sales beats indicate continued operating momentum. Haemonetics Tops Q1 Earnings and Revenue Estimates
• Positive Sentiment: Management raised its fiscal 2027 outlook and now expects reported revenue growth of approximately 5% to 8%. The improved forecast, following a strong first quarter, supports the view that demand and execution are better than previously anticipated. Haemonetics Raises Fiscal 2027 Revenue Guidance
• Positive Sentiment: BTIG Research raised its Haemonetics price target from $84 to $96 and maintained a “buy” rating, implying additional upside based on the company’s earnings performance and outlook. BTIG Raises Haemonetics Price Target
• Neutral Sentiment: Citigroup lifted its price target from $79 to $92, while retaining a “neutral” rating. The higher target reflects improved estimates but suggests limited conviction at the current valuation. Citigroup Analyst Update
• Neutral Sentiment: JPMorgan raised its target from $62 to $86 but maintained a “neutral” rating. The revised target remains slightly below the recent trading level, signaling that valuation may constrain further gains despite the improved outlook. JPMorgan Analyst Update

About Haemonetics

Haemonetics Corporation is a global provider of blood management solutions that support the collection, processing and transfusion of blood and blood products. The company’s offerings are designed to enhance patient safety and operational efficiency for blood centers, hospitals and plasma collection facilities. Haemonetics serves healthcare providers worldwide by delivering integrated systems, software and consumables that address critical needs throughout the continuum of blood management.

The company’s product portfolio includes automated apheresis and plasma collection systems, surgical blood salvage and coagulation monitoring devices, and pathogen reduction technologies.